This is clearly a smaller proportion than in small cell lung carcinomas (SCLC), where up to 90% of tumors exhibit TP53 mutations [16], which is therefore considered a driver mutation in the pathogenesis of SCLC. Here, TP53 is linked to small cell lung carcinoma.